Corvus Pharmaceuticals

Update in progress

CRVS (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Corvus Pharmaceuticals, Inc. is a South San Francisco-based clinical-stage biopharma founded in 2014. It develops targeted immune therapies, led by soquelitinib (CPI-818), a covalent ITK inhibitor in a multi-center Phase 1b/2 trial for several cancers and inflammatory diseases. It also pursues ciforadenant (CPI-444), an A2A receptor antagonist in Phase 2 for first-line renal cell cancer, and mupadolimab (CPI-006) in Phase 1 for non-small cell lung cancer. The company licenses CXCR2 antibodies from Monash, adenosine receptor assets from Vernalis, and mupadolimab licenses from Scripps.

Company score

Sentiment: 0.42; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.34; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.27; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.22; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.32; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive